Charles yu md9/10/2023 Furthermore, crucial molecular factors can also be screened via the transgenic approach, which may eventually play a major role in the development of therapeutic strategies against diseases like Alzheimer's or Parkinson's. Neurofluorescent reporters can be used to study the structural patterns of nerves in the central or peripheral nervous system in vivo, as well as phenomena involving embryologic or adult neurogenesis, injury, degeneration, and recovery. One important application of transgenic species is the study of the cytoarchitecture of the nervous system. By placing fluorescent reporters under the direct regulation of the promoter region of specific marker proteins, these models can localize and characterize very specific cell types. Therearetensofthousandsofpatientswhosufferfromcornealblindnessduetoaccidents,diseases, willalsocreateanewdevicewhichcanbeusedbysurgeonstoreplacedamagedcorneasandrestore visiontoblindpatients.Recombinant DNA technologies have enabled the development of transgenic animal models for use in studying a myriad of diseases and biological states. This study offers the opportunity to both study the pathophysiology leading to keratoprosthesis complications and create a useful corneal replacement which can be implanted through a small wound and does not require donor corneal tissue. This study proposes the development of a easy to implant minimally invasive keratoprosthesis (MiKpro) device, which can be implanted into the cornea through a 3 mm trephination without use of donor cornea tissue. Also there is potential for design advances to reduce the complexity of surgical implantation and need for donor cornea tissue. There is a gap in the current understanding of why prosthetic membranes form and why there is often relentless membrane formation or glaucoma in these patients despite placement of pressure regulating glaucoma drainage devices. These complications occur at a rate of up to 65% and 76%, respectively. However BKpro remains limited by its technical difficulty and rate of complications such as extrusion, infection, and particularly membrane formation and glaucoma. The 5 year success rate varies from 50-70% depending on study. Currently in these situations a Boston Keratoprosthesis Type I (BKpro) can be performed. In cases where corneal stem cells have been damaged or there is vascularity, transplantation cannot be performed due to risk of rejection. When injured by disease or dysfunction the cornea becomes opaque, causing scattering of light and loss of visual function. A normal cornea is transparent and curved, focusing light from the outside world. Research The cornea comprises the outer anterior layer of the eye. The department commits over 22,000 square feet of its physical space to research. The research program encompasses the most critical areas of vision research, including investigations into the causes and pathology of blinding diseases, the development of innovative techniques and instruments for diagnosing and monitoring the progression of eye disease, genome-wide association studies of retinal diseases and visual functioning and retinal processes. The department has a total of 47 full time faculty members, with 24 of them engaged in basic science or translational research. Environment The University of Illinois Eye and Ear Infirmary is one of the largest centers of vision research in the US, ranking top 4 in NIH funding in the last fiscal year. During this training period he will take numerous courses in engineering and materials science and complete two internships to develop his skill in polymer chemistry and industrial design. He is currently an assistant professor and a K12 scholar at the University of Illinois Eye and Ear Infirmary. He has a strong background in the basic sciences having completed numerous research projects and a Howard Hughes Medical Institute sponsored medical research fellowship. He is an expert in corneal innervation, developing artificial corneas and animal models of eye disease, ocular infections, and refractive surgery clinical trials. Yu is a fellowship trained ophthalmologist specializing in corneal blindness and has a deep interest in developing new technologies to cure blindness. Yu to become an independent investigator, this program may have a significant impact on the treatment of corneal blindness through the development of a new corneal replacement technology. In additional to the primary goal of training Dr. Charles Yu in the scientific skills and knowledge necessary for a career as an independent scientist translating scientific discoveries to clinically useful applications, specifically the restoration of vision in patients with corneal blindness. The objective of this grant application is to train Dr.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |